The role of age and salivation in acid clearance in symptomatic patients with gastro-oesophageal reflux disease

Citation
Wc. Orr et al., The role of age and salivation in acid clearance in symptomatic patients with gastro-oesophageal reflux disease, ALIM PHARM, 15(9), 2001, pp. 1385-1388
Citations number
24
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Pharmacology,"da verificare
Journal title
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
ISSN journal
0269-2813 → ACNP
Volume
15
Issue
9
Year of publication
2001
Pages
1385 - 1388
Database
ISI
SICI code
0269-2813(200109)15:9<1385:TROAAS>2.0.ZU;2-G
Abstract
Background: Cisapride has been shown to have not only prokinetic effects, b ut also salivary stimulating effects. Both of these mechanisms play an impo rtant role in the acid clearance of the oesophagus. Aim: To access the efficacy of cisapride in facilitating acid clearance in patients with symptomatic gastrooesophageal reflux disease. Methods: Fifteen older adults and 15 younger adults with symptomatic gastro -oesophageal reflux disease completed the study. The acid clearance test wa s accomplished by infusing 15 mL of 0.1 N HCl into the distal oesophagus, a nd the number of swallows was determined to achieve an oesophageal pH of 4. 0. This was accomplished under baseline conditions and salivary stimulation with a peppermint lozenge. After 1 week of treatment with cisapride (10 mg , q.d.s.), the acid clearance test was repeated. Results: The lozenge produced a significant decrease in the number of swall ows compared to baseline in both groups (P < 0.01). There was a significant decrease in the number of swallows after the treatment with cisapride comp ared to baseline in both groups (P < 0.01). No significant difference was f ound in the number of swallows when comparing cisapride with lozenge. Conclusions: Cholinergic stimulation of salivation is an effective means of facilitating oesophageal acid clearance. Drugs, such as 5 hydroxytriptamin e (5-HT)(4)-receptor agonists, should be considered as potentially importan t compounds in the treatment of gastrooesophageal reflux disease.